IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1375.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 3-Jun-2015
Heart
Cancer overtakes cardiovascular disease as UK's No. 1 killer -- but only among men
Cancer has overtaken cardiovascular disease, which includes heart disease and stroke, as the UK's No. 1 killer -- but only among men, reveals research published online in the journal Heart.

Contact: Caroline White
cwhite@bmj.com
44-798-080-0465
BMJ

Public Release: 3-Jun-2015
ACS Central Science
Antibody fragments expand what PET imaging can 'see' in mice (video)
To visualize cancer throughout the body, physicians often turn to positron emission tomography, which lights up areas that are metabolically active or growing, like tumors. Today in ACS Central Science, researchers report development of new PET probes composed of labeled antibody fragments that were tested in mice. These probes could someday be used to create targeted probes, giving doctors more information about tumors and how to treat them.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 3-Jun-2015
New England Journal of Medicine
Attending breast cancer screening reduces risk of death by 40 percent
Women aged 50-69 years who attend mammography screening reduce their risk of dying from breast cancer by 40 percent compared to women who are not screened -- according to a major international review of the latest evidence on breast cancer screening.

Contact: Charli Scouller
c.scouller@qmul.ac.uk
44-770-982-5741
Queen Mary, University of London

Public Release: 3-Jun-2015
2015 ASCO Annual Conference
JAMA Surgery
Benefit of surgery for ductal carcinoma in-situ investigated
In a study published in JAMA Surgery on June 3, researchers from Brigham and Women's Hospital report that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) did not significantly change patients' survival rate. The team finds that the survival rate for those with intermediate- and high-grade DCIS does improve with surgery, but the work raises concerns about overtreatment and the necessity and benefit of surgery for all patients with low-grade DCIS.

Contact: Haley Bridger
hbridger@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 2-Jun-2015
2D Materials
Improving the delivery of chemotherapy with graphene
A new study published in IOP Publishing's journal 2D Materials has proposed using graphene as an alternative coating for catheters to improve the delivery of chemotherapy drugs.

Contact: Steve Pritchard
steve.pritchard@iop.org
44-117-930-1032
Institute of Physics

Public Release: 2-Jun-2015
Molecular Cell
Scientists discover a protein that silences the biological clock
A new study led by UC Santa Cruz researchers has found that a protein associated with cancer cells is a powerful suppressor of the biological clock that drives the daily ('circadian') rhythms of cells throughout the body. The discovery adds to a growing body of evidence suggesting a link between cancer and disruption of circadian rhythms, while offering new insights into the molecular mechanisms of the biological clock.
National Institutes of Health, UK Cancer Research Programme

Contact: Tim Stephens
stephens@ucsc.edu
831-459-4352
University of California - Santa Cruz

Public Release: 2-Jun-2015
2015 ASCO Annual Conference
Study finds misperceptions about impact of double mastectomy
A survey of women with breast cancer found that nearly half considered having a double mastectomy. But of those who considered it, only 37 percent knew that the more aggressive procedure does not improve survival for women with breast cancer.
NIH/National Cancer Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 2-Jun-2015
Cell Cycle
'Master controller' behind DNA structure reorganization during senescence identified
Scientists at the Wistar Institute have identified how a specific variant of a key protein complex found in human cells called condensin can reorganize a cell's genetic architecture in such a way as to promote senescence, making it an important facilitator in a cell's anticancer ability.
W.W. Smith Charitable Trust, V Foundation, Edward Mallinckrodt Jr. Foundation

Contact: Darien Sutton
dsutton@wistar.org
215-898-3988
The Wistar Institute

Public Release: 2-Jun-2015
Gastroenterology
Microendoscope could eliminate unneeded biopsies
In a clinical study of patients in the United States and China, researchers found that a portable, low-cost, battery-powered microendoscope developed by Rice University bioengineers could eventually eliminate the need for costly biopsies for many patients undergoing standard endoscopic screening for esophageal cancer.
NIH/National Cancer Institute

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 1-Jun-2015
2015 ASCO Annual Conference
Mount Sinai researchers to present key cancer trial data at ASCO
Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 -- June 2, 2015, in Chicago.

Contact: Lucia Lee
lucia.lee@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 1-Jun-2015
Cancer Prevention Research
Western diet may increase risk of death after prostate cancer diagnosis
After a prostate cancer diagnosis, eating a diet higher in red and processed meat, high-fat dairy foods, and refined grains -- known as a Western diet -- may lead to a significantly higher risk of both prostate cancer-related mortality and overall mortality compared with eating a diet rich in vegetables, fruits, fish, whole grains, and healthy oils, according to a new study from Harvard T.H. Chan School of Public Health.
US Department of Defense, National Institutes of Health, Prostate Cancer Foundation, Boston Nutrition and Obesity Research Center, Harvard TREC Center, Dana-Farber/Harvard Cancer Center, SPORE in Prostate Cancer

Contact: Marge Dwyer
mhdwyer@hsph.harvard.edu
617-432-8416
Harvard School of Public Health

Public Release: 1-Jun-2015
2015 ASCO Annual Conference
Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma
PharmaMar today announced data from the Phase 2 ATREUS study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2 percent of patients treated with the anticancer drug trabectedin in second line were alive and free of progression at 12 weeks. The median progression-free survival in these 17 evaluated patients was 8.3 weeks. The study will be presented at the 2015 ASCO Annual Meeting.

Contact: Carolina Pola
cpola@pharmamar.com
34-608-933-677
Pharmamar

Public Release: 1-Jun-2015
2015 ASCO Annual Conference
PharmaMar's PM1183 plus doxorubicin shows remarkable activity in small cell lung cancer
PharmaMar today announced data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer showing that the treatment induced objective responses in 67 percent of the patients, including 10 percent of them where all signs of cancer disappeared (complete responses). The study will be presented at 2015 ASCO Annual Meeting in Chicago.

Contact: Carolina Pola
cpola@pharmamar.com
34-608-933-677
Pharmamar

Public Release: 1-Jun-2015
Canadian Medical Association Journal
Canada's radon guidelines are inadequate
Radon gas is a silent health threat, and Canada needs to align its guidelines for acceptable radon levels with World Health Organization limits, argues an editorial in Canadian Medical Association Journal.

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-521-7116
Canadian Medical Association Journal

Public Release: 1-Jun-2015
Cancer Research
Common antibiotic part of a new potential pancreatic cancer therapy
A new promising combination therapy has been discovered for the treatment of one of the most deadly and difficult cancers to manage. VCU Massey Cancer Center and VCU Institute of Molecular Medicine scientists developed a novel combination of an experimental drug and a common antibiotic that has shown encouraging results in treating pancreatic cancer in preclinical experiments.
NIH/National Cancer Institute , VCU Massey Cancer Center

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 1-Jun-2015
Nature
Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors
Cleveland Clinic researchers have discovered for the first time that a metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone, has more anti-cancer properties than its precursor. The research will be published online June 1st in Nature.
Prostate Cancer Foundation, American Cancer Society, US Department of Defense (US Army Medical Research and Material Command), Howard Hughes Medical Institute, NIH/National Cancer Institute

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic

Public Release: 1-Jun-2015
2015 ASCO Annual Conference
Trials show immune drugs effective in advanced melanomas
Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack.

Contact: Erika Matich
erika.matich@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 1-Jun-2015
Molecular Cancer
Noncoding RNA CCDC26 regulates KIT expression
A long noncoding RNA (lncRNA), which might give an impact on tyrosine kinase-targeted leukemia therapy, was found to be expressed in a leukemia cell line. The function of the lncRNA CCDC26 is not fully understood; however, researchers at Hiroshima University revealed the mechanisms by which CCDC26 controls the receptor tyrosine kinase KIT expression. The results provide new insights into leukemia recurrence and may help to develop new leukemia therapies.
Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research

Contact: Norifumi Miyokawa
pr-research@office.hiroshima-u.ac.jp
Hiroshima University

Public Release: 1-Jun-2015
Advanced Material Interfaces
New sensing tech could help detect diseases, fraudulent art, chemical weapons
Discovered in the 1970s, SERS is a sensing technique prized for its ability to identify chemical and biological molecules in a wide range of fields. It has been commercialized, but not widely. That may soon change. An international research team led by University at Buffalo engineers has developed nanotechnology that promises to make SERS simpler and more affordable.
National Science Foundation

Contact: Cory Nealon
cmnealon@buffalo.edu
716-645-4614
University at Buffalo

Public Release: 1-Jun-2015
Nature
Salk scientists reveal epigenome maps of the human body's major organs
This new atlas of human organ epigenomes provides a starting place to understand the role of chemical markers in development, health and disease.

Contact: Salk Communications
press@salk.edu
858-453-4100
Salk Institute

Public Release: 31-May-2015
2015 ASCO Annual Conference
New England Journal of Medicine
Immunotherapy drug improves survival for common form of lung cancer
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies.
Bristol-Myers Squibb

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 31-May-2015
2015 ASCO Annual Conference
New England Journal of Medicine
Immunotherapy combo increases progression-free survival in advanced melanoma patients
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center simultaneously presented today at the 2015 American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.
Bristol-Myers Squibb

Contact: Caitlin Hool
hoolc@mskcc.org
646-227-3956
Memorial Sloan Kettering Cancer Center

Public Release: 31-May-2015
2015 ASCO Annual Conference
Risks of whole brain radiation therapy outweigh benefits for patients with limited brain metastases
Whole Brain Radiation Therapy is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 31-May-2015
2015 ASCO Annual Conference
Duke's poliovirus study finds that less is more
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered.

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 31-May-2015
Journal of Clinical Investigation
Discovery could improve radiotherapy for wide range of cancers
Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today.
Cancer Research UK

Contact: Liz Smith
liz.smith@cancer.org.uk
020-346-98300
Cancer Research UK

Showing releases 201-225 out of 1375.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

  Search News Releases

     

 

EurekAlert!